# Lisata Therapeutics (LSTA) — News

LSTA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lsta/news

## Recent headlines

- [Lisata Therapeutics - Board expanded from seven to eight members with newly created seat](https://www.ainvest.com/news/lisata-therapeutics-board-expanded-members-newly-created-seat-2610) — AInvest Wire, Oct 14, 2026
  Lisata Therapeutics, Inc. (Nasdaq: LSTA) has expanded its board of directors from seven to eight members with the creation of a new seat, according to the company’s corporate governance information . The addition brings the total number of board members to eight, with the new appointee expected to…
- [Lisata Therapeutics appoints Jeff Farrow to board of directors](https://www.ainvest.com/news/lisata-therapeutics-appoints-jeff-farrow-board-directors-2610) — AInvest Wire, Oct 14, 2026
- [Lisata Therapeutics announces new method of use patent granted for Certepetide in the treatment of pancreatic cancer and other solid tumors](https://www.ainvest.com/news/lisata-therapeutics-announces-method-patent-granted-certepetide-treatment-pancreatic-cancer-solid-tumors-2610) — AInvest Wire, Oct 8, 2026
- [Lisata Therapeutics, - To use net proceeds to advance Mar001/005 and Mar002 with topline phase 2 data expected Q4 2027](https://www.ainvest.com/news/lisata-therapeutics-net-proceeds-advance-mar001-005-mar002-topline-phase-2-data-expected-q4-2027-2609) — AInvest Wire, Sep 17, 2026
  Lisata Therapeutics is utilizing net proceeds from recent financing to advance its pipeline of investigational therapies, including MAR001 and MAR002. The company is preparing for key clinical milestones, with topline data from Phase 2 trials expected in the fourth quarter of 2027. MAR001 is…
- [Lisata Therapeutics: Investors to receive 150,867.995 Series C preferred shares at $1,491.37 per share](https://www.ainvest.com/news/lisata-therapeutics-investors-receive-150-867-995-series-preferred-shares-1-491-37-share-2609) — AInvest Wire, Sep 17, 2026
  Lisata Therapeutics, Inc. has announced that investors will receive 150,867.995 Series C preferred shares at a price of $1,491.37 per share. This offering is part of the company’s ongoing capital-raising efforts and is intended to support its operations and development initiatives. The transaction…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).